Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance

被引:31
作者
Boswell, FJ [1 ]
Andrews, JM [1 ]
Jevons, G [1 ]
Wise, R [1 ]
机构
[1] City Hosp NHS Trust, Dept Microbiol, Birmingham B18 7QH, W Midlands, England
关键词
D O I
10.1093/jac/dkf152
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In this study the in vitro activities and pharmacodynamic properties of moxifloxacin, levofloxacin, gatifloxacin and gemifloxacin were compared on recently isolated respiratory pathogens and strains of Streptococcus pneumoniae with known mechanisms of fluoroquinolone resistance. In addition, the resistance selection frequencies of moxifloxacin and levofloxacin on three recently isolated respiratory pathogens and four strains of S. pneumoniae with known mechanisms of fluoroquinolone resistance were investigated. The four fluoroquinolones had similar activities against both Moraxella catarrhalis (MIC(90)s 0.015-0.06 mg/L) and Haemophilus influenzae (MIC(90)s 0.008-0.03 mg/L). More marked differences in activity were noted with S. pneumoniae, with MIC(90)s of 0.25, 1, 0.5 and 0.03 mg/L for moxifloxacin, levofloxacin, gatifloxacin and gemifloxacin, respectively. With the S. pneumoniae strains, the four fluoroquinolones exhibited similar concentration-dependent time-kill kinetics. The resistance selection frequencies of levofloxacin were higher than those of moxifloxacin at concentrations equivalent to those at the end of the dosing interval. Therefore moxifloxacin may have less of an impact on the development of resistance than levofloxacin.
引用
收藏
页码:495 / 502
页数:8
相关论文
共 26 条
[1]   Engineering the specificity of antibacterial fluoroquinolones:: Benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase [J].
Alovero, FL ;
Pan, XS ;
Morris, JE ;
Manzo, RH ;
Fisher, LM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :320-325
[2]   Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy [J].
Andrews, JM ;
Honeybourne, D ;
Jevons, G ;
Brenwald, NP ;
Cunningham, B ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (04) :573-577
[3]   A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus:: Evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux [J].
Beyer, R ;
Pestova, E ;
Millichap, JJ ;
Stosor, V ;
Noskin, GA ;
Peterson, LR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :798-801
[4]   Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect [J].
Boswell, FJ ;
Andrews, JM ;
Wise, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1377-1379
[5]   Grepafloxacin vs pneumococci resistant to fluoroquinolones by a putative efflux mechanism [J].
Brenwald, NP ;
Gill, MJ ;
Wise, R .
DRUGS, 1999, 58 (Suppl 2) :117-118
[6]   Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae [J].
Brenwald, NP ;
Gill, MJ ;
Wise, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2032-2035
[7]  
*BRIT SOC ANT CHEM, 2001, J ANTIMICROBIAL SS1, V48, P5
[8]   THE IN-VITRO ACTIVITY OF CP-99,219, A NEW NAPHTHYRIDONE ANTIMICROBIAL AGENT - A COMPARISON WITH FLUOROQUINOLONE AGENTS [J].
CHILD, J ;
ANDREWS, J ;
BOSWELL, F ;
BRENWALD, N ;
WISE, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 35 (06) :869-876
[9]  
Eliopoulos G. M., 1993, P161
[10]   Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model:: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses [J].
Firsov, AA ;
Lubenko, IY ;
Vostrov, SN ;
Kononenko, OV ;
Zinner, SH ;
Portnoy, YA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (05) :725-732